Navigation Links
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Date:5/31/2008

ions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
2. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
3. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
4. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
7. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
8. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
9. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
10. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
11. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
(Date:1/22/2015)... WOODBRIDGE, ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics ... company with a focus on Omega-3 therapies for cardiovascular disease ... summary of the Company,s accomplishments in 2014 and its outlook ... Dear Fellow Shareholders, We would like ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... in Carotid Atherosclerosis, LEXINGTON, Mass., Oct. 24 ... its pivotal clinical trial (PROVIDENCE-1),studying the effect of ... peripheral arterial disease (PAD) will be,presented on November ... late breaker,Scientific Session at the American Heart Association,s ...
... Today the National Legal and Policy,Center (NLPC) asked ... for,International Development (USAID) to investigate the possibility that ... groups operating,needle exchange programs for drug users in ... activist George,Soros are recipients of these legally questionable ...
Cached Medicine Technology:ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting 2ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting 3Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups 2
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on ... anniversary of the Supreme Court decision Roe v. Wade, which legalized ... the Roe vs. Wade decision and the fight to protect a ... City of West Hollywood Councilmember Abbe Land. “We need to continue ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently ... thrilled to have it lead the wedding dress industry into ... prom dresses for the global market. , “The CEO of ... he focuses on continuing the goal of operational excellence and ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... increasing pressure to provide access to expensive new drugs. ... not publicly insured are seeking to pay for these ... CMAJ ( Canadian Medical Association Journal ) (pre-embargo ... by Colleen M. Flood, Canada Research Chair in Health ...
... Patients should avoid taking the two drugs together, researchers ... Women with breast cancer who take both tamoxifen and ... because Paxil reduces tamoxifen,s effectiveness, Canadian researchers report. , ... especially when it is used in combination with tamoxifen ...
... , ... stories are physicians reading to stay informed about key developments? MedPage Today ... Stories for the Past Week will be published Every Monday and will ... of Herbal Meds Reviewed , ICU Catheter Infections ...
... CLEARWATER, Fla. , Feb. 8 Lincare Holdings Inc. ... and year ended December 31, 2009 . , For the quarter ... , compared with net revenues of $415.1 million for the ... net revenues in the fourth quarter of 2009 was comprised of 13% ...
... CHARLOTTE, N.C. , Feb. 8 Medical teams from ... Haiti . Through an agreement with the Department of the Navy, CHS ... providing care to victims of the January earthquake. , The first ... will remain in Haiti for two weeks.  Navy medical officials ...
... Paolo Pandolfi, at Beth Israel Deaconess Medical Center, Boston, ... irreversible arrest of cell growth) and determined a way ... growth in mice. Previous work by Pandolfi and ... to a senescence response that opposes tumorigenesis. In this ...
Cached Medicine News:Health News:Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer 2Health News:Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer 3Health News:MedPage Today(R) 'What Your Physicians Are Reading' 2Health News:MedPage Today(R) 'What Your Physicians Are Reading' 3Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 2Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 3Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 4Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 5Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 6Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 7Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 8Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 9Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 10Health News:Carolinas HealthCare System Volunteers to Join Navy Rescue Mission in Haiti 2Health News:Carolinas HealthCare System Volunteers to Join Navy Rescue Mission in Haiti 3
... The Vasotrax is an ... pressure and heart rate non-invasively, ... fact, significantly more accurate than ... On a full battery charge, ...
... (IGF-II) is a 7.5 kDa peptide which is ... to have mitogenic and metabolic actions involved in ... by binding to target cell receptors. IGF-II binds ... receptor, a monomeric protein which also serves as ...
... Leptin is a proteohormone with a molecular weight ... by the ob gene and produced by adipocytes [1,2]. ... in the regulation of body weight [1-3]. In ... in both men and women [4]. A relationship ...
... is synthesized by the parathyroid glands ... decreased extracellular calcium concentrations. PTH prevents ... decreasing calcium excretion by the kidney. ... PTH is rapidly degraded into 4 ...
Medicine Products: